Pfizer’s Oral COVID-19 Pill Paxlovid Tops Merck’s Molnupiravir
Pfizer reported its protease inhibitor Paxlovid showed an 89% risk reduction for hospitalization and death compared to placebo in interim results of a Phase II/III trial. The pharma now is seeking a quick EUA in the US.
You may also be interested in...
US government is paying Merck & Co. around $181 more per course of treatment for its oral antiviral for COVID-19, molnupiravir, than it is to Pfizer for its competing drug.
Pfizer CEO Albert Bourla discussed the emergency use authorization filing for Paxlovid, expanding access to the COVID-19 pill in lower income countries and booster shots, at the STAT Summit.
An agreement allowing the production and distribution of the US firm’s new protease inhibitor in 95 countries has been welcomed by the Medicines Patent Pool. But some medicines access advocates are not so sure it necessarily represents a good deal for lower-income countries.